NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $14.14 +0.06 (+0.43%) (As of 11/29/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Dr. Reddy's Laboratories Stock (NYSE:RDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RDY alerts:Sign Up Key Stats Today's Range$14.10▼$14.2150-Day Range$13.99▼$15.9852-Week Range$12.90▼$16.89Volume565,482 shsAverage Volume1.02 million shsMarket Capitalization$11.80 billionP/E Ratio22.59Dividend Yield0.57%Price Target$17.00Consensus RatingHold Company OverviewDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks29th Percentile Overall ScoreRDY MarketRank™: Dr. Reddy's Laboratories scored higher than 29% of companies evaluated by MarketBeat, and ranked 854th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3.61% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 3.61% in the coming year, from $0.83 to $0.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 22.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 22.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 65.44.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.39% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.57%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 12.78%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.30% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.39% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.30 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Dr. Reddy's Laboratories this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for RDY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address RDY Stock News HeadlinesWhat is Zacks Research's Estimate for RDY FY2025 Earnings?November 29 at 2:26 AM | americanbankingnews.comDr. Reddy's Launches Toripalimab For Nasopharyngeal Carcinoma In IndiaNovember 28 at 12:13 PM | markets.businessinsider.comTODAY ONLY: Nvidia’s Silent Partners RevealedThanks to a specific AI Blueprint … A small handful of companies have already soared as much as 562%, 3,247% and even 6,583%. Now, with a massive recent $1 trillion pivot to data centers, six NEW stocks could be next in line to follow this pattern.December 1, 2024 | Weiss Ratings (Ad)Dr. Reddy’s Fined in Germany for Registration LapseNovember 28 at 7:13 AM | markets.businessinsider.comDr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinomaNovember 28 at 6:15 AM | businesswire.comDr. Reddy’s and Senores launch Ivermectin tablets USP, 3 mg in U.S.November 26, 2024 | markets.businessinsider.comDr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US MarketNovember 26, 2024 | businesswire.comDr. Reddy’s Gains Strong Rating Amid Robust GrowthNovember 20, 2024 | markets.businessinsider.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $13.9160 at the beginning of the year. Since then, RDY shares have increased by 1.6% and is now trading at $14.14. View the best growth stocks for 2024 here. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings results on Wednesday, January, 31st. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.02. The business earned $867 million during the quarter, compared to analysts' expectations of $827.81 million. Dr. Reddy's Laboratories had a net margin of 17.81% and a trailing twelve-month return on equity of 18.53%. When did Dr. Reddy's Laboratories' stock split? Dr. Reddy's Laboratories's stock split on the morning of Tuesday, November 5th 2024. The 5-1 split was announced on Thursday, September 12th 2024. The newly created shares were payable to shareholders after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Dr. Reddy's Laboratories' top institutional investors include Robeco Institutional Asset Management B.V. (1.24%), Aikya Investment Management Ltd (0.13%), State Street Corp (0.11%) and Fisher Asset Management LLC (0.06%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings1/31/2024Today11/30/2024Next Earnings (Estimated)1/29/2025Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,048Year Founded1984Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+20.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.6260 Trailing P/E Ratio22.59 Forward P/E Ratio17.04 P/E GrowthN/ANet Income$668 million Net Margins17.81% Pretax Margin23.95% Return on Equity18.53% Return on Assets13.01% Debt Debt-to-Equity Ratio0.02 Current Ratio1.92 Quick Ratio1.36 Sales & Book Value Annual Sales$3.35 billion Price / Sales3.52 Cash Flow$1.02 per share Price / Cash Flow13.88 Book Value$4.42 per share Price / Book3.20Miscellaneous Outstanding Shares834,700,000Free Float818,007,000Market Cap$11.80 billion OptionableOptionable Beta0.56 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:RDY) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts